Probatebeta
Target

FGFR1

Fibroblast growth factor receptor 1

As of the edition of 20 October 2026, FGFR1 (fibroblast growth factor receptor 1, UniProt P11362) has 22 drugs tested at it and 26 companies on the list, 11 on route A and 7 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P11362
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
93
Disease areas
Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue; Inherited and neonatal
Registered trials of its drugs
780

Drugs at this target

StatusCount
Marketed7
Active3
Went quiet4
Stopped7
Status not established1
Total22
DrugStatusFurthest phaseUS protection
RegorafenibMarketedPhase 4Ends 2032
NintedanibMarketedPhase 4Ends 2027
SurufatinibActivePhase 4none listed
PemigatinibMarketedPhase 3Ends 2040
ErdafitinibMarketedPhase 3Ends 2033
InfigratinibMarketedPhase 3Ends 2029
FutibatinibMarketedPhase 3Ends 2036
FexagratinibActivePhase 3none listed
BrivanibStoppedPhase 3none listed
LucitanibStoppedPhase 3none listed
RogaratinibStoppedPhase 3none listed
XL-999Went quietPhase 2none listed

12 of 22 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A11
Route B7
Engaged3
Undetermined5
Total on the list26
Three companies on route A or B, with the route only
CompanyRoute
IncyteRoute B
Bristol Myers SquibbRoute A
AstraZenecaRoute A

The other 23 companies at FGFR1

In the product

26 companies in all; 23 are not named here, and no score is.

See the 26 companies at FGFR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at FGFR1

Other targets in cancer

Companies holding approvals at FGFR1